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https://doi.org/10.1002/aoc.4902A complete protocol for the synthesis of new palladacyclopentadienyl
complexes with purine‐based carbenes as supporting ligands is described.
The new organometallic compounds were exhaustively characterized using
NMR and infrared spectroscopies and elemental analysis. The single‐crystal
X‐ray structure of complex 2b coordinating also a triphenylphosphine was
resolved. Some of these complexes showed an antiproliferative activity compa-
rable to or better than that of cisplatin on two human ovarian cancer lines:
A2780 (cisplatin‐sensitive) and A2780cis (cisplatin‐resistant). Moreover, for
complexes 2 and 3 (coordinating one purine‐based N‐heterocyclic carbene
ligand and one phosphine) the cytotoxicity is associated with an evident
induction of apoptosis. Finally, complexes 3, bearing one purine‐based
N‐heterocyclic carbene ligand and one 1,3,5‐triaza‐7‐phosphaadamantane,
proved practically inactive on non‐tumour fibroblast cells (MRC‐5).
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palladacyclopentadienyl complexes, purine bases1 | INTRODUCTION
In recent years a number of different platinum complexes
have been synthesized with the aim of reproducing, or
possibly enhancing, the therapeutic properties ofwileyonlinelibrary.comcisplatin and its analogues of second and third genera-
tion.[1,2] It is worth noting that such compounds still rep-
resent the most widely used chemotherapeutic metallo‐
drugs active in the battle against neoplastic pathologies
despite the resistance mechanism developed by some© 2019 John Wiley & Sons, Ltd./journal/aoc 1 of 16
2 of 16 SCATTOLIN ET AL.typology of neoplasia,[3] their remarkable toxicity and
their reduced versatility towards several tumours. On
the other hand, the development of synthetic analogues
might be of great interest in lowering the toxicity or
implementing the multidrug approach to cancer therapy.
Moreover, the multiplicity of possible cellular targets
and/or the difficulty of predicting the mechanism of
interaction with biomolecules mean that it is very
demanding to plan on paper the structure and features
of a new metal chemotherapeutic drug.
Therefore, no impressive improvements have been
obtained so far.[4] One alternative approach to the prob-
lem is based on investigating systematically unexplored
classes of metal compounds. The possibility of choosing
ancillary ligands and organometallic fragments offers
many variables, from a combination of which might
emerge a new effective chemotherapeutic drug.[5,6]
In this respect, palladium might represent a valid
alternative to platinum because of the similarity among
the structures of their complexes. On the other hand,
palladium derivatives show a better solubility in water
and a markedly enhanced reactivity with respect to those
of platinum.[7,8] In this context, it was recently shown
that palladium complexes stabilized by strong ligands
often display a higher anticancer activity than the usual
platinum agents.[9]
On the basis of such observations, we have recently car-
ried out a study describing the synthesis of several allyl
palladium complexes stabilized by various N‐heterocyclic
carbene (NHC) spectator ligands derived from three
appropriately functionalized methylxanthines[10] which
show an antiproliferative activity, in many cases markedly
higher than that of the reference cisplatin.11a We have
planned this sort of investigation accepting some
literature suggestions. Firstly, we supposed that the easier
dissociation path in bloodstream and/or cellular environ-
ment of palladium complexes compared to platinum
derivatives8b, c could be reduced by strong stabilizing
NHC ligands.[12] In this respect it is worth noting that
some NHC–palladium derivatives described in theliterature display reduced cytotoxicity[9a,d,13] and a notice-
able cancer growth suppression in vivo.[9d,12e] Secondly,
the natural origin of xanthines suggested a possible
increased compatibility and therefore an enhanced
interaction of the related derivatives with the biological
environment, as already shown elsewhere.[14]
In the work presented here and at variance with previ-
ous work focused on the palladium–allyl moiety,11a we
opted for the palladacyclopentadienyl group since it was
shown that palladacycles can be very effective against
various cancer cell lines.9d Moreover, the experience we
developed on these substrates[15] suggests that this organ-
ometallic fragment should remain stable in a biological
environment.
As supporting ligands, in addition to purine‐based
NHCs, we chose triphenylphosphine (PPh3), 2,6‐dimethyl-
phenylisocyanide (DIC) and 1,3,5‐triaza‐7‐phosphada-
mantane (PTA), with the aim of obtaining complexes
with different steric and electronic features. In particular,
it is well known that PTA can increase the water solubility
of its derivatives.[16]
The structures of the palladacyclopentadienyl deriva-
tives synthesized and tested against the A2780 (cisplatin‐
sensitive) and A2780cis (cisplatin‐resistant) cancer lines
are reported in Scheme 1.2 | RESULTS AND DISCUSSION
2.1 | Synthesis of purine‐based
imidazolium salts
Compounds a–c were obtained pure and in quantitative
yields by metathesis of tetrafluoroborate ions with
tetraphenylarsonium chloride of alkylated xanthines, syn-
thesized according to methods published elsewhere[11]
(Figure S1a, supporting information).
The chloride derivatives were characterized using 1H
NMR and 13C NMR spectroscopy and the spectra of com-
pounds a–c display slight modification with respect toSCHEME 1 Starting imidazolium salts
(a–c) and palladacyclopentadienyl
derivatives (1–4)
SCATTOLIN ET AL. 3 of 16those of the original tetrafluoroborate derivatives (Figure
S1b‐g, supporting information). In particular, the marked
downfield shift (ca 1.5 ppm) of the barely significant
imidazolic proton is worth noting.2.2 | Synthesis of silver purine‐based NHC
complexes
The reaction of compounds a–c with Ag2O carried out in
CH3CN for 4 h in the dark yielded the silver complexes
Aga–c (Scheme 2).
A comparison between the NMR spectra of the starting
alkylated xanthines and the ensuing silver complexes
confirms that the reaction summarized in Scheme 2 took
place. As can be seen (Figure S2a–d,g–j, supporting infor-
mation), the peak of the imidazole proton disappears and
all the signals belonging to alkyl and aryl groups undergo
a shift upon coordination with the metal. The complete
assignment of the signals has been carried out on the
basis of the two‐dimensional HSQC and HMBC NMR
spectra. However, the true molecular structure of com-
plexes Aga–c was assigned by means of ESI‐MS, which
indicates that the carbene silver complexes, according to
the suggestion of Nolan and co‐workers,[17] are better
described as [(NHC)Ag(NHC)][AgCl2] rather than the
simpler [(NHC)Ag(NHC)]Cl (Figure S2e,f, supporting
information).2.3 | Synthesis of bis‐NHC
palladacyclopentadienyl complexes
The synthesis of the title complexes was carried out
according to Scheme 3. Complexes 1 were synthesized
by reacting compounds Aga–c and the polymericSCHEME 2 Synthesis of silver purine‐based NHC complexes
SCHEME 3 Synthesis of complexes 1precursor [PdC4(COOCH3)]n. The synthesis was con-
ducted according to published methods.[11,18] Despite
the difficulty we have hitherto faced when bulky carbenes
are used for the preparation of bis‐carbene complexes,15e
the synthesis of derivatives 1 proceeded without particu-
lar problems and they were obtained in reasonable yields.
The NMR spectra, however, are characterized by the
doubling of all the signals ascribable to the synthesized
complexes, as can be noticed in Figure 1 and Figure S3
(supporting information). In the case of complexes 1c
(Figure 1) and 1b, an AB system, due to the presence of
two non‐equivalent CH2Ph groups, together with the
already cited doubling of all the other signals, strongly
suggest the concomitant and essentially equimolecular
formation of two atropoisomers in which the benzyl
fragments lie on the same or opposite side of the main
plane of the complexes owing to the hindered rotation
about the Pd─C bond of the non‐symmetric carbene
(Figure 2).
The detailed 1H NMR and 13C NMR investigations,
supported by HSQC and HMBC spectra (Figure S3,
supporting information), confirm the structure in solu-
tion of complexes 1. In particular:
i) the carbenic NCH3 groups of any atropoisomer
resonate at chemical shifts different from those of
the silver complexes.
ii) Twodifferent couple of signals for theOCH3 groups in
both the 1H NMR and 13C NMR spectra are detected.
iii) The already cited AB signal ascribable to the CH2Ph
benzyl protons in the case of complexes 1b and 1c is
observed.
iv) Two different carbene carbon signals are observed at
ca 188 ppm.2.4 | Synthesis of mixed NHC–PPh3
palladacyclopentadienyl complexes (2)
As a consequence of a detailed study entailing theoretical
approaches and experimental controls,[20] we were able to
prepare pure complexes 2 using the non‐conventional
synthetic methodology reported in Scheme 4. This
FIGURE 1 1H NMR spectrum of
complex 1c (CDCl3, T = 298 K)
FIGURE 2 Density functional theory representation[19] of the atropoisomers of complex 1b (for the sake of optimization of computer time,
the COOMe group was substituted with the less disordered CN)
4 of 16 SCATTOLIN ET AL.methodology does not always lead to the formation of the
mixed complexes since well‐defined thermodynamic and
kinetic conditions must be obeyed in order to avoid the for-
mation of the bis‐carbene and bis‐phosphino complexes
only, or a mixture of all the possible derivatives. A prelimi-
nary density functional theory study of the thermodynamic
stability of the involved species[19] (Figure S4, supporting
information) and consequent experimental results showthat in this and in other cases (discussed below) the precon-
ditions elsewhere identified[20] have been satisfied.
The characterization of complexes 2 was carried out
using NMR and infrared (IR) spectroscopies (Figures S5,
supporting information) and in the case of complex 2b
by the diffractometric resolution of its solid‐state structure.
The 31P{1H}NMR spectra of the complexes show a sin-
gle signal at ca 25–26 ppm at lower field than that of freeSCHEME 4 Synthesis of complexes 2
SCATTOLIN ET AL. 5 of 16PPh3 (ca 30 ppm) (Figure S5a, supporting information).
Due to the asymmetry induced by the different spectator
ligands, the 1H NMR and 13C NMR spectra of all the
complexes show four signals related to the COOMe
groups (Figure S5b,c,g–j, supporting information).
In the 1HNMR spectra, all the NCH3 protons are clearly
detectable whereas those belonging to the CH2Ph groups
in the case of complexes 2b and 2c resonate as AB systems
owing to their magnetic non‐equivalence induced by the
hindered rotation of the carbene about the Pd─C bond.
Finally, the carbene carbon resonates as a doublet at ca
190 ppm owing to the coupling with vicinal phosphorus.
As a definitive confirmation of the steric nature of
these complexes, we show in Figure 3 the resolved solid‐
state structure of complex 2b which will be discussed later
on. Other ORTEP[21] representations of complex 2b are
shown in Figure S8 (supporting information).2.5 | Synthesis of mixed NHC–PTA
palladacyclopentadienyl complexes (3)
As can be seen in Scheme 5, also in this case the thermo-
dynamic and kinetic conditions yielding these complexes
by direct synthesis were fulfilled.FIGURE 3 Ellipsoid representation of 2b crystal ASU contents
(50% probability)
SCHEME 5 Synthesis of complexes 3The NMR investigations confirm the nature of the title
derivatives and the related NMR and IR spectra are
shown in Figure S6 (supporting information). Thus, in
the 1H NMR investigation, the singlets ascribable to the
NCH3 groups belonging to all the complexes and the AB
systems of the NCH2 fragments of complexes 3b and 3c
are detected in the range 3.40–4.20 and 5.00–6.50 ppm,
respectively. The NCH2N and NCH2P protons of the
coordinated PTA resonate in the range 4.30–4.50 and
3.50–4.00 ppm, respectively, whereas the four OCH3
groups are observed between 3.2 and 3.8 ppm.
In the 13C{1H}NMR spectra, the carbene carbon
resonates in the range 180–190 ppm as a doublet (JC–
P ≈ 17–18 Hz) whereas NCH2P and NCH2N are detected
at ca 50 ppm (doublet, JC–P ≈ 10 Hz) and 73 ppm (doublet,
JC–P ≈ 6 Hz), respectively.2.6 | Synthesis of mixed NHC–DIC
complexes (4)
Despite the electronic difference between the good
π‐acceptor DIC and the other ligands used in this research,
which are all σ‐donating molecules although to different
degrees, the synthetic protocol yielding complexes 4
remains almost the same as those previously described
(Scheme 6). As amatter of fact, themost relevant difference
between the protocols is the reaction rate, which in this
case is considerably lower (48 h) than those related to the
formation of complexes 1–3 (1 h). Moreover, soon after
the mixing of the reagents, three complexes, namely the
bis‐substituted isocyanide, bis‐substituted carbene and
mixed palladacyclopentadienyl derivative 4, are detected
in solution. These kinds of reaction are not unprecedented
and have been recently studied in detail.[20] Eventually, the
thermodynamically stable mixed species 4 were exhaus-
tively formed and the long time necessary for the comple-
tion of the reaction is mainly due to the steric hindrance
induced by the bulky homogeneously substituted bis‐
carbene and bi‐isocyanide palladacyclopentadienyl com-
plexes reacting with each other.[22]
The characterization of complexes 4 was carried out
using NMR and IR spectroscopies and the related spectra
are reported in the supporting information (Figure S7a–i).
SCHEME 6 Synthesis of complexes 4
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NCH3 groups are observed as singlets in the range
3.35–4.35 ppm, whereas in the case of complexes 4b and
4c the AB systems of the benzyl NCH2 protons are
detected in the range 5.10–6.00 ppm. The four OCH3
fragments resonate in the range 3.29–3.81 ppm whereas
the isocyanide methyl groups, at variance with those of
the free moiety, are observed as singlets in the range
2.00–2.50 ppm.
In the 13C{1H}NMR spectra, the isocyanide and the
carbene carbons are easily observed at ca 149 and in the
range 180–190 ppm, respectively.TABLE 2 Effects of complexes on proliferation of A2780 and
A2780cis cells. The inhibition of cell growth is represented as IC50.
DMSO stock solutions (50 mM) of the complexes were diluted with
EtOH to obtain working solutions. Cisplatin was dissolved in water
Complex
IC50 (μM)
A2780 (IC50) A2780cis (IC50)
Cisplatin 0.6 ± 0.1 6 ± 1
[PdC4(COOCH3)4]n >100 >100
1a 9.0 ± 0.7 7.03 ± 0.01
1b 6.5 ± 0.5 5.53 ± 0.06
1c 81 ± 4 60 ± 3
2a 5.3 ± 0.7 6.7 ± 0.82.7 | X‐ray diffraction analysis: structural
characterization of 2b
The crystalline form of 2b contains one crystallographi-
cally independent palladium complex (Figure 3). Palla-
dium centres adopt square planar coordination spheres
with bond lengths and angles (Table 1) in agreement with
literature structural data of complexes with similar
ligands. The CSD database (version 5.39 – November
2017) reports only one alternative Pd (II)–xanthine com-
plex showing compatible Pd─C bond length (2.008(14)
Å).[23] Furthermore, the molecular model of 2b is well
superimposable with the related (2,6‐dimethylpheny-
lisocyanide)‐(1,2,3,4‐tetrakis(methoxycarbonyl)buta‐1,3‐d
iene‐1,4‐diyl)‐(triphenylphosphine)palladium structure
(green sticks; CCDC no. 825712) complex[24] (CCDC no.
714135); RMSD of common atoms shared by the two
models is 0.81 Å (Figure S9, supporting information).
The structure of 2b shows that the xanthine minimizes
steric repulsions in the solid state, adopting a roughlyTABLE 1 Selected bond distances and angles for the palladium
coordination sphere of 2b. Naming schemes are reported in Figure 3
Bond Length (Å) Angle Value (°)
Pd_1–C1_3 2.0757(17) C1_3–Pd_1–C4_3 80.08(7)
Pd_1–C4_3 2.0647(18) C1_3–Pd_1–P_2 95.81(5)
Pd_1–P_2 2.3367(8) P_2–Pd_1–C8_4 92.83(5)
Pd_1–C8_4 2.0379(17) C8_4–Pd_1–C4_3 91.21(7)perpendicular orientation with respect to the palladium
coordination plane (69.48° in 2b). Neighbour ligand
sidechains (a phenyl from the phosphine and one
carbomethoxy from the buta‐1,3‐diene‐1,4‐diyl ligand)
adopt conformations parallel to the xanthine, with
average plane distances of 3.1(5) Å suggesting that π···π
interligand contacts might stabilize the complex. Crystal
packing shows hydrophobic contacts among neighbour
molecules, involving several CH···π and minor π···π
interactions, while water molecules are trapped in polar
cavities where hydrogen bonds link carbomethoxy groups
of neighbour palladium complexes.2.8 | Antiproliferative activity
The complexes containing PTA (3a–c) are very soluble in
water. All other complexes are scarcely soluble in water,
and for this reason the stock solutions (50 mM) for2b 5.0 ± 0.2 5.25 ± 0.05
2c 6.66 ± 0.03 16 ± 1
3a 4.3 ± 0.7 0.65 ± 0.2
3b 0.9 ± 0.1 1.0 ± 0.3
3c 0.56 ± 0.08 0.62 ± 0.07
4a 3.3 ± 0.6 2.1 ± 0.4
4b 1.6 ± 0.3 1.8 ± 0.9
4c 0.7 ± 0.05 0.87 ± 0.09
SCATTOLIN ET AL. 7 of 16biological investigations were prepared in dimethylsul-
foxide (DMSO) and the working solutions were then
obtained by dilution with ethanol.
The stability of the complexes was preliminarily
checked in D2O (3) or DMSO‐d6 (1, 2 and 4): after
48 h at room temperature no ligand replacement and
no degradation were observed. The ability of all the syn-
thesized complexes in inhibiting the cell proliferation of
ovarian cancer cells A2780 and A2780cis was analysed
after 72 h treatment, in order to explore their biological
activity in comparison with cisplatin, a known antineo-
plastic agent. The two cell lines exhibited a sharply dif-
ferent response to cisplatin exposure. One (A2780) was
sensitive to cisplatin, while the other (A2780cis) wasTABLE 3 Effects of complexes on proliferation of MRC‐5 human
fibroblasts. The inhibition of cell growth is represented as IC50.
DMSO stock solutions (50 mM) of the complexes were diluted with
EtOH to obtain working solutions. Cisplatin was dissolved in water
Complex IC50 (μM)
Cisplatin 14 ± 1
2b 30 ± 15
3c >100
FIGURE 4 Representative apoptosis profiles of A2780 cells untreated
with complexes 1b, 2b, 3c and 4c at various concentrations (IC50 and IC
diluted with ethanol to obtain working solutions. Cisplatin was dissolvecisplatin resistant. In Table 2, the results obtained from
three independent experiments are reported. The strong
antiproliferative activity of cisplatin (IC50 = 0.6 ± 0.1 μM)
on the A2780 cell line was confirmed;[11,25] in addition,
the obtained data confirmed the cisplatin resistance of
the A2780cis cell line (IC50 = 6 ± 1 μM). For all the
complexes investigated, with the exception of 2c, the
IC50 values against the A2780 and A2780cis cell lines
were similar, indicating that they were active also on
the resistant cell line. Notably, compound 3a exhibited
higher activity on A2780cis cells with respect to A2780
cells. The compounds exhibiting the highest in vitro anti-
proliferative activity (IC50 ≤ 1 μM) were 3a, 3b, 3c and
4c. All these compounds displayed a very interesting
ability in inducing cytotoxicity in both the cell lines,
featuring higher activity than cisplatin against the resis-
tant cells.
In order to preliminarily evaluate a potential selectiv-
ity of the palladacyclopentadienyl complexes against can-
cer cells, normal human fibroblasts (MRC‐5) were treated
for 72 h with complexes 2b and the most effective 3c. As
evident from Table 3, the compounds are poorly active
(2b) or inactive (3c) against this non‐tumour cell line,
suggesting a preferential activity of the analysed com-
pounds against cancer cells.(C−), treated for 72 h with cisplatin (C+; 0.5 and 1.0 μM) and treated
75 values). DMSO stock solutions (50 mM) of the complexes were
d in water
8 of 16 SCATTOLIN ET AL.2.9 | Pro‐apoptotic effects
In order to verify whether the antiproliferative activity of
the newly synthesized compounds is associated with the
activation of the apoptotic pathway (as is known when
cisplatin is administered to tumour cells of various ori-
gins),[26–29] the complexes of each series demonstratingFIGURE 5 Representative apoptosis profiles of A2780cis cells untrea
treated with complexes 1b, 2b, 3c and 4c at various concentrations (IC5
complexes were diluted with ethanol to obtain working solutions. Cispl
TABLE 4 Pro‐apoptotic effects of complexes on A2780 and A2780cis c
stock solutions (50 mM) of the complexes were diluted with EtOH to ob
Total apoptosis (%) Dead cells (
Complex A2780 A2780
C− 3.14 4.03
Cisplatin 26.7 (0.5 μM) 0.95 (0.6 μM)
55.9 (1.0 μM) 0.55 (1.0 μM)
1b 88.38 (6.5 μM) 0.58 (6.5 μM)
87.59 (9.0 μM) 0.56 (9.0 μM)
2b 88.38 (5.0 μM) 0.47 (5.0 μM)
84.96 (7.5 μM) 0.33 (7.5 μM)
3c 47.99 (0.6 μM) 0.78 (0.6 μM)
76.15 (0.8 μM) 0.85 (0.8 μM)
4c 6.21 (0.7 μM) 1.67 (0.7 μM)
14.22 (1.0 μM) 6.23 (1.0 μM)the best antiproliferative activity (1b, 2b, 3c, 4c) were
investigated. The Annexin V test and a MUSE cell
analyser were employed for this purpose. Representative
results are shown in Figures 4 and 5, and all the obtained
data are summarized in Table 4. All the selected deriva-
tives, with the exception of 4c, induced evident apoptosis
in both cell lines. These assays have been performedted (C−), treated for 72 h with cisplatin (C+; 1.0 and 5.0 μM) and
0 and IC75 values). DMSO stock solutions (50 mM) of the
atin was dissolved in water
ell lines detected at two concentrations. (C−, untreated cells). DMSO
tain working solutions. Cisplatin was dissolved in water
%) Total apoptosis (%) Dead cells (%)
A2780cis A2780cis
8.53 4.12
13.50 (1.0 μM) 0.95 (1.0 μM)
27.40 (5.0 μM) 0.20 (6.0 μM)
11.46 (5.5 μM) 8.13 (5.5 μM)
21.87 (8.5 μM) 2.95 (8.5 μM)
77.38 (5 μM) 0.50 (5 μM)
77.96 (8 μM) 0.40 (8 μM)
41.87 (0.6 μM) 3.10 (0.6 μM)
52.47 (0.9 μM) 5.60 (0.9 μM)
15.30 (0.9 μM) 3.02 (0.9 μM)
10.91 (1.3 μM) 1.99 (1.3 μM)
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mine expected antiproliferative effects, i.e. the IC50 and
IC75 values against A2780 and A2780cis cell lines.
Cisplatin was added to the cultured cells, demonstrating
its evident and already reported pro‐apoptotic effects on
the A2780 cell line, when used at 1.0 μM concentration
(55.9% of total apoptosis), while on the resistant
A2780cis cells it was inactive at the same concentration.
When the compounds were assayed on the A2780 cell
line, at the used concentrations, the best pro‐apoptotic
activity was obtained with the complexes 1b, 2b and 3c
which were able to induce a very high percentage of
apoptosis, exhibiting a better pro‐apoptotic activity than
cisplatin (Figure 4 and Table 3). Fully in agreement with
the data shown in Table 2, derivatives 2b and 3c induced
pro‐apoptotic effects also on the resistant A2780cis cells.
Compound 1b displayed low pro‐apoptotic effects on
A2780cis cells, whereas it was active on A2780 cells,
suggesting a different mechanism of action with respect
to compounds 2b and 3c.3 | CONCLUSIONS
We have synthesized twelve new palladacyclopentadienyl
complexes bearing two NHCs or one NHC and one
phosphine or isocyanide. In order to enhance the biolog-
ical affinity of the complexes, three different compounds
derived from modified natural xanthines were used as
NHC ligands.
The cytotoxicity of the complexes towards the ovarian
cancer cellular lines A2780 (cisplatin‐sensitive) and
A2780cis (cisplatin‐resistant) was determined. Notably,
with the exception of the bis‐carbene derivative 1c, all
the synthesized complexes show an antiproliferative
activity comparable to that of cisplatin.
A correlation between the antiproliferative activity of
the derivatives and their structure has been observed. In
particular, the less hindered complexes of the type
NHC–PTA or NHC–DIC show a higher efficiency with
respect to the bis‐NHC and the NHC–PPh3 derivatives.
Complexes 3 proved particularly promising since they
are able to associate a significant antiproliferative activity,
especially on A2780cis line, with the ability to induce
apoptosis. Moreover, complex 3c, which is the most
active species, is almost inactive against non‐tumour cells
(MRC‐5 fibroblasts).
This observation might be important in view of possi-
ble application of the studied compounds in anticancer
treatments, suggesting that preclinical investigations
using different primary tumour cell isolates should be
considered before proposing these compounds for clinical
trials. In addition, it will be necessary in the future toinvestigate the activity using in vivo model systems, in
order to clarify whether the described cytotoxicity against
tumour cell lines involves negligible side effects on
normal cells and networks.
Finally, the presence of PTA makes complexes 3 very
soluble in water, a requisite that is very important for
drug administration.
The natural development of this work will be to define
the main cellular target and the mechanism of action of
the most promising complexes.4 | EXPERIMENTAL
4.1 | Solvents and reagents
The solvents CH2Cl2 and CH3CN were distilled over
CaH2. Acetone was refluxed over 4 Å molecular sieves
and distilled. The precursor [PdC4(COOCH3)4]n was
synthesized according to published procedures.[18] All
other solvents and chemicals were commercial‐grade
products and used as purchased.4.2 | IR and NMR spectroscopic
measurements and elemental analysis
The IR and 1H NMR, 13C NMR and 31P NMR spectra
were recorded with a PerkinElmer Spectrum One spectro-
photometer and Bruker Avance 300 or Ascend 400
spectrometers, respectively. The elemental analysis of
the synthesized complexes was carried out using an
Elementar CHN CUBO Micro Vario analyser. ESI‐MS
analyses were carried out by the group of Prof. Sgarbossa
(Padua University).4.3 | Crystal structure determinations
The crystal data of compound 2b were collected at 100 K
at the XRD1 beamline of the Elettra Synchrotron, Trieste
(Italy).[30] The datasets were integrated, scaled and
corrected for Lorentz and polarization effects with the
XDS package.[31] The structure was solved by direct
methods using the SHELXT program[32] and refined
using full‐matrix least‐squares with all non‐hydrogen
atoms anisotropically and hydrogens included on calcu-
lated positions, riding on their carrier atoms. Disordered
water molecules were modelled in cavities, located on
crystallographic inversion centres. The electron content
per void area has been estimated to be 14e− (ca 70 Å3;
PLATON[33] SQUEEZE routine), in agreement with
refined water occupancies. Hydrogen atoms for water
molecules were not included in the refined models since
10 of 16 SCATTOLIN ET AL.it was not possible to locate them unambiguously in
electron‐density peaks of Fourier difference maps
(contributions of these missing hydrogen atoms are still
included in the properties reported in Table S1,
supporting information). All calculations were performed
using SHELXL‐2018/3.[34] The Coot program was used
for structure building.[35] The crystal data are given in
Table S1 (supporting information). Pictures were pre-
pared using Ortep3[21] software.
Crystallographic data have been deposited at the
Cambridge Crystallographic Data Centre and allocated
the deposition number CCDC 1881566. These data can
be obtained free of charge via https://www.ccdc.cam.ac.
uk/structures.4.4 | Synthesis of purine‐based
imidazolium salts (a–c)
These compounds were synthesized by chloride–BF4
metathesis of each tetrafluoroborate imidazolium salt
obtained according to published procedures.[11]4.4.1 | Compound a
To 356.2 mg (1.203 mmol) of the tetrafluoroborate salt of
tetramethylcaffeine, dissolved in 100 ml of water,
503.9 mg (1.203 mmol) of AsPh4Cl was added. The imme-
diate formation of AsPh4BF4 as a white fluffy precipitate
was observed. The reaction mixture was stirred for ca
30 min and AsPh4BF4 was filtered off using a Millipore
apparatus. The clear solution was dried under vacuum
at low temperature (< 50°C) and the residue ground in
20 ml of CH2Cl2, filtered off using a Gooch filter, washed
with diethyl ether and dried under vacuum. An amount
of 293.3 mg (yield 99%) of compound a was obtained as
a white solid.
1H NMR (400 MHz, CD3CN, T = 298 K, δ, ppm): 3.34
(s, 3H, NCH3), 3.75 (s, 3H, NCH3), 4.13 (s, 3H, NCH3),
4.21 (s, 3H, NCH3), 10.03 (s, 1H, NCHN).
13C{1H} NMR
(CD3CN, T = 298 K, δ, ppm): 28.6 (CH3, NCH3), 31.8
(CH3, NCH3), 36.2 (CH3, NCH3), 37.5 (CH3, NCH3),
108.8 (C, C5), 140.1 (C, C4), 140.4(CH, N─CH─N), 151.1
(C, C═O), 154.2 (C, C═O). IR (KBr): νC═O = 1719,
1675 cm−1, νC─O = 1304, 1264 cm
−1.
Compounds b and c were prepared in a similar way
from the appropriate reactants.4.4.2 | Compound b
White solid; yield 98%. 1H NMR (400 MHz, CD3CN,
T = 298 K, δ, ppm): 3.33 (s, 3H, NCH3), 3.73 (s, 3H,NCH3), 4.10 (s, 3H, NCH3), 5.72 (s, 2H, NCH2),
7.44–7.50 (m, 5H, Ph), 8.92 (s, 1H, NCHN). 13C{1H}
NMR (CD3CN, T = 298 K, δ, ppm): 28.2 (CH3, NCH3),
31.2 (CH3, NCH3), 37.3 (CH3, NCH3), 52.0 (CH2, NCH2),
107.8 (C, C5), 128.6–133.4 (Ph), 138.6 (CH, NCHN),
140.0 (C, C4), 150.4 (C, C═O), 153.4 (C, C═O). IR (KBr):
νC═O = 1717, 1671 cm
−1, νC─O = 1267 cm
−1.4.4.3 | Compound c
White solid; yield 99%. 1H NMR (400 MHz, CD3CN,
T = 298 K, δ, ppm): 3.73 (s, 3H, NCH3), 4.09 (s, 3H,
NCH3), 4.10 (s, 3H, NCH3), 5.16 (s, 2H, NCH2),
7.33–7.39 (m, 5H, Ph), 8.82 (s, 1H, NCHN). 13C{1H}
NMR (CD3CN, T = 298 K, δ, ppm): 31.3 (CH3, NCH3),
35.8 (CH3, NCH3), 37.0 (CH3, NCH3), 45.0 (CH2, NCH2),
108.6 (C, C5), 127.7–136.5 (Ph), 139.0 (CH, NCHN),
139.8 (C, C4), 150.4 (C, C═O), 153.5 (C, C═O). IR (KBr):
νC═O = 1722, 1674 cm
−1.4.5 | Synthesis of silver purine‐based NHC
complexes (Aga–c)
4.5.1 | Complex Aga
To 142.5 mg (0.5824 mmol) of compound a, dissolved in
35 ml of anhydrous CH3CN in a two‐necked flask under
inert atmosphere (argon), 74.2 mg (0.320 mmol) of
Ag2O was added. The mixture was vigorously stirred in
the dark for 4 h and a fluffy white solid, which was fil-
tered off using a Gooch filter, was progressively formed.
The white solid was dissolved in 200 ml of CH2Cl2 and
from the resulting mixture the Ag2O in excess removed
by filtration in a Millipore apparatus. The clear solution
was concentrated under vacuum and the complex Aga
precipitated as white solid by addition of diethyl ether,
filtered off using a Gooch filter and dried under vacuum.
An amount of 121.4 mg of the title complex was obtained
(yield 60%).
1H NMR (400 MHz, CD2Cl2, T = 298 K, δ, ppm): 3.41
(s, 6H, 2NCH3), 3.84 (s, 6H, 2NCH3), 4.17 (s, 6H, 2NCH3),
4.24 (s, 6H, 2NCH3).
13C{1H} NMR (DMSO‐d6, T = 298 K,
δ, ppm): 28.7 (CH3, NCH3), 31.2 (CH3, NCH3), 32.0 (CH3,
NCH3), 38.3 (CH3, NCH3), 109.3 (C, C
5), 140.9 (C, C4),
151.0 (C, C═O), 153.7 (C, C═O), 207.0 (C, carbene).
ESI‐MS (CH3CN): m/z 525.04 [Ag(NHC)2]
+. IR (KBr):
νC═O = 1709, 1669 cm
−1.
Derivatives Agb and Agc were prepared in a similar
way from the appropriate reactants.
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White solid; yield 67%. 1H NMR (400 MHz, CDCl3,
T = 298 K, δ, ppm): 3.31 (s, 6H, 2NCH3), 3.73 (s, 6H,
2NCH3), 4.16 (s, 6H, 2NCH3), 5.62 (s, 4H, 2NCH2),
7.20–7.41 (m, 10H, 2Ph). 13C{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 28.8 (CH3, NCH3), 32.0 (CH3,
NCH3), 40.1 (CH3, NCH3), 54.1 (CH2, NCH2), 109.1 (C,
C5), 128.3–135.5 (Ph), 140.3 (C, C4), 150.6 (C, C═O),
153.1 (C, C═O), 188.1 (C, carbene). ESI‐MS (CH3CN):
m/z 677.11 [Ag(NHC)2]
+. IR (KBr): νC═O = 1713,
1673 cm−1.4.5.3 | Complex Agc
White solid; yield 70%. 1H NMR (400 MHz, CDCl3,
T = 298 K, δ, ppm): 3.83 (s, 6H, 2NCH3), 4.15 (s, 6H,
2NCH3), 4.19 (s, 6H, 2NCH3), 5.19 (s, 4H, 2NCH2),
7.29–7.50 (m, 10H, 2Ph). 13C{1H} NMR (DMSO‐d6,
T = 298 K, δ, ppm): 31.2 (CH3, NCH3), 32.1 (CH3,
NCH3), 38.3 (CH2, NCH2), 109.3 (C, C
5), 127.7–137.3
(Ph), 141.3 (C, C4), 150.9 (C, C═O), 153.5 (C, C═O),
206.9 (C, carbene). ESI‐MS (CH3CN): m/z 677.08
[Ag(NHC)2]
+. IR (KBr): νC═O = 1711, 1674 cm
−1.4.6 | Synthesis of bis‐NHC
palladacyclopentadienyl complexes (1)
4.6.1 | Complex 1a
In a 50 ml two necked flask, 18.2 mg (0.0466 mmol) of
[PdC4(COOCH3)4]n was dissolved in 5 ml of anhydrous
CH2Cl2 under inert atmosphere (argon). An amount of
27.3 mg (0.0388 mmol) of complex Aga, suspended in
25 ml of anhydrous CH2Cl2, was added to the solution
of [PdC4(COOCH3)4]n and precipitation of AgCl was
immediately observed. The mixture was reacted for 1 h
at room temperature and then filtered using a Millipore
apparatus. The clear yellow solution was concentrated
under vacuum and the title complex precipitated by addi-
tion of diethyl ether. The yellow microcrystalline precipi-
tate was filtered off using a Gooch filter, washed with
diethyl ether and dried under vacuum. An amount of
21.3 mg (70% yield) of complex 1a was obtained.
1H NMR (400 MHz, CD2Cl2, T = 298 K, δ, ppm): 3.30
(s, 12H, 4 OCH3), 3.36 (s, 12H, 4NCH3), 3.61 (s, 12H, 4
OCH3), 3.78 (s, 6H, 2NCH3), 3.79 (s, 6H, 2NCH3), 4.11
(s, 6H, 2NCH3), 4.15 (s, 6H, 2NCH3), 4.32 (s, 6H,
2NCH3), 4.34 (s, 6H, 2NCH3).
13C{1H} NMR (CD2Cl2,
T = 298 K, δ, ppm): 28.3 (CH3, NCH3), 31.8 (CH3,
NCH3), 37.2 (CH3, NCH3), 37.4 (CH3, NCH3), 39.2 (CH3,
NCH3), 39.3 (CH3, NCH3), 50.6 (CH3, OCH3), 51.0 (CH3,OCH3), 109.8 (C, C
5), 140.5 (C, C4), 144.6 (C,
C─COOCH3), 150.6 (C, C═O), 153.0 (C, C═O), 164.8 (C,
COOCH3), 164.9 (C, COOCH3), 167.1 (C, C─COOCH3),
167.2 (C, C─COOCH3), 175.7 (C, COOCH3), 175.9 (C,
COOCH3), 188.1 (C, carbene), 188.4 (C, carbene). IR
(KBr): νC═O = 1710, 1672 cm
−1, νC─O = 1209 cm
−1. Anal.
Calcd for C30H36N8O12Pd (%): C 44.65, H 4.50, N 13.88.
Found (%): C 44.77, H 4.38, N 13.80.
Derivatives 1b and 1c were prepared in a similar way
from the appropriate reactants.4.6.2 | Complex 1b
Yellow microcrystals; yield 91%. 1H NMR (400 MHz,
CD2Cl2, T = 298 K, δ, ppm): 3.27 (s, 12H, 4 OCH3), 3.29
(s, 12H, 4NCH3), 3.43 (s, 6H, 2NCH3), 3.61 (s, 6H, 2
OCH3), 3.63 (s, 6H, 2 OCH3), 3.75 (s, 6H, 2NCH3), 3.79
(s, 6H, 2NCH3), 4.32 (s, 6H, 2NCH3), 4.98 and 5.40 (AB
system, 4H, J = 15.5 Hz, 2NCH2), 5.77 and 5.85 (AB sys-
tem, 4H, J = 16.3 Hz, 2NCH2), 6.90–7.33 (m, 20H, 4Ph).
13C{1H} NMR (CD2Cl2, T = 298 K, δ, ppm): 28.3 (CH3,
NCH3), 31.5 (CH3, NCH3), 31.9 (CH3, NCH3), 38.4 (CH3,
NCH3), 39.4 (CH3, NCH3), 50.6 (CH3, OCH3), 51.0 (CH3,
OCH3), 52.7 (CH2, NCH2), 109.0 (C, C
5), 109.5 (C, C5),
125.1–136.7 (Ph), 140.7 (C, C4), 140.8 (C, C4), 145.1 (C,
C─COOCH3), 145.2 (C, C─COOCH3), 150.4 (C, C═O),
150.5 (C, C═O), 152.3 (C, C═O), 164.8 (C, COOCH3),
165.1 (C, COOCH3), 166.7 (C, C─COOCH3), 167.1 (C,
C─COOCH3), 175.4 (C, COOCH3), 188.6 (C, carbene),
189.1 (C, carbene). IR (KBr): νC═O = 1710, 1668 cm
−1,
νC─O = 1206 cm
−1. Anal. Calcd for C42H44N8O12Pd (%):
C 52.59, H 4.62, N 11.68. Found (%): C 52.74, H 4.79, N
11.57.4.6.3 | Complex 1c
Yellow microcrystals; yield 80%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 3.28 (s, 6H, 2 OCH3), 3.31 (s,
6H, 2 OCH3), 3.62 (s, 6H, 2 OCH3), 3.64 (s, 6H, 2 OCH3),
3.74 (s, 6H, 2NCH3), 3.78 (s, 6H, 2NCH3), 4.09 (s, 6H,
2NCH3), 4.13 (s, 6H, 2NCH3), 4.35 (s, 6H, 2NCH3), 4.36
(s, 6H, 2NCH3), 5.14 (m, 8H, 4NCH2), 7.27–7.40 (m,
20H, 4Ph). 13C{1H} NMR (CDCl3, T = 298 K, δ, ppm):
31.9 (CH3, NCH3), 32.0 (CH3, NCH3), 37.4 (CH3, NCH3),
37.6 (CH3, NCH3), 39.4 (CH3, NCH3), 39.6 (CH3, NCH3),
45.1 (CH2, NCH2), 50.8 (CH3, OCH3), 51.3 (CH3, OCH3),
109.9 (C, C5), 127.9–136.3 (Ph), 140.7 (C, C4), 140.8 (C,
C4), 145.0 (C, C─COOCH3), 145.3 (C, C─COOCH3),
150.4 (C, C═O), 152.9 (C, C═O), 165.0 (C, COOCH3),
165.2 (C, COOCH3), 166.6 (C, C─COOCH3), 166.9 (C,
C─COOCH3), 176.1 (C, COOCH3), 176.2 (C, COOCH3),
188.3 (C, carbene), 189.1 (C, carbene). IR (KBr):
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−1, νC─O = 1208 cm
−1. Anal. Calcd
for C42H44N8O12Pd (%): C 52.59, H 4.62, N 11.68. Found
(%): C 52.74, H 4.56, N 11.67.4.7 | Synthesis of mixed NHC–PPh3 and
NHC–PTA palladacyclopentadienyl
complexes (2 and 3)
4.7.1 | Complex 2a
In a 50 ml two‐necked flask, 27.9 mg (0.0713 mmol) of
[PdC4(COOCH3)4]n was dissolved in 5 ml of anhydrous
CH2Cl2 under inert atmosphere (argon). An amount of
21.8 mg (0.0310 mmol) of complex Aga and 17.1 mg
(0.0651 mmol) of PPh3, suspended in 30 ml of anhydrous
CH2Cl2, were added to the solution of [PdC4(COOCH3)4]n
and precipitation of AgCl was immediately observed. The
mixture was reacted for 1 h at room temperature and
then filtered using a Millipore apparatus. The clear
yellow solution was concentrated under vacuum and
the title complex precipitated by addition of diethyl ether.
The yellow microcrystalline precipitate was filtered off
using a Gooch filter, washed with diethyl ether and dried
in a desiccator. An amount of 509 mg (83% yield) of
complex 2a was obtained.
1H NMR (400 MHz, CDCl3, T = 298 K, δ, ppm): 2.53 (s,
3H, OCH3), 3.25 (s, 3H, OCH3), 3.36 (s, 3H, NCH3), 3.48
(s, 3H, NCH3), 3.63 (s, 3H, OCH3), 3.65 (s, 3H, OCH3),
3.76 (s, 3H, NCH3), 3.82 (s, 3H, NCH3), 7.32–7.51 (m,
15H, 3Ph). 13C{1H} NMR (CDCl3, T = 298 K, δ, ppm):
28.6 (CH3, NCH3), 31.5 (CH3, NCH3), 36.6 (CH3, NCH3),
38.2 (CH3, NCH3), 50.0 (CH3, OCH3), 50.8 (CH3, OCH3),
51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 109.7 (C, C
5),
128.3–134.1 (Ph), 140.2 (C, C4), 145.9 (d, C, JC–P = 5.4 Hz,
C─COOCH3), 148.8 (d, C, JC–P = 7.0 Hz, C─COOCH3),
150.2 (C, C═O), 152.7 (C, C═O), 164.0–166.4 (C,
COOCH3), 168.1 (C, C─COOCH3), 169.6 (C,
C─COOCH3), 174.9 (d, C, JC–P = 4.9 Hz, COOCH3),
175.6 (d, C, JC–P = 5.3 Hz, COOCH3), 189.1 (d, C,
JC–P = 15.8 Hz, carbene).
31P{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 26.1. IR (KBr): νC═O = 1730,
1692 cm−1, νC─O = 1212 cm
−1. Anal. Calcd for
C39H39N4O10PPd (%): C 54.39, H 4.56, N 6.51. Found
(%): C 54.49, H 4.51, N 6.62.
Derivatives 2b, 2c, 3a, 3b and 3c were prepared in a
similar way from the appropriate reactants.4.7.2 | Complex 2b
Yellow microcrystals; yield 86%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 2.56 (s, 3H, OCH3), 3.04 (s,
3H, OCH3), 3.38 (s, 3H, NCH3), 3.46 (s, 3H, NCH3), 3.63(s, 3H, OCH3), 3.64 (s, 3H, OCH3), 3.85 (s, 3H, NCH3),
5.40 and 5.50 (AB system, 2H, J = 14.2 Hz, NCH2),
7.12–7.52 (m, 20H, 4Ph). 13C{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 28.7 (CH3, NCH3), 31.8 (CH3,
NCH3), 39.0 (CH3, NCH3), 50.0 (CH3, OCH3), 50.9 (CH3,
OCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 53.6 (CH2,
NCH2), 109.5 (C, C
5), 128.2–134.7 (Ph), 140.9 (C, C4),
148.8 (d, C, JC–P = 5.6 Hz, C─COOCH3), 149.0 (d, C, JC–
P = 7.3 Hz, C─COOCH3), 150.3 (C, C═O), 152.7 (C,
C═O), 164.9–165.1 (C, COOCH3), 166.0 (C, C─COOCH3),
166.4 (C, C─COOCH3), 174.5 (d, C, JC–P = 5.2 Hz,
COOCH3), 174.9 (d, C, JC–P = 6.4 Hz, COOCH3), 189.4
(d, C, JC–P = 15.5 Hz, carbene).
31P{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 25.1. IR (KBr): νC═O = 1710,
1670 cm−1, νC─O = 1208 cm
−1. Anal. Calcd for
C45H43N4O10PPd (%): C 57.67, H 4.62, N 5.98. Found
(%): C 57.81, H 4.73, N 5.87.4.7.3 | Complex 2c
Yellow microcrystals; yield 85%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 2.53 (s, 3H, OCH3), 3.24 (s,
3H, OCH3), 3.48 (s, 3H, NCH3), 3.63 (s, 3H, OCH3), 3.65
(s, 3H, OCH3), 3.80 (s, 6H, 2NCH3), 5.08 and 5.13 (AB
system, 2H, J = 14.5 Hz, NCH2), 7.24–7.50 (m, 20H,
4Ph). 13C{1H} NMR (CDCl3, T = 298 K, δ, ppm): 31.6
(CH3, NCH3), 36.6 (CH3, NCH3), 38.3 (CH3, NCH3), 45.0
(CH2, NCH2), 49.9 (CH3, OCH3), 50.8 (CH3, OCH3), 51.2
(CH3, OCH3), 51.3 (CH3, OCH3), 109.9 (C, C
5),
128.0–136.5 (Ph), 140.1 (C, C4), 145.9 (d, C, JC–P = 5.5 Hz,
C─COOCH3), 148.8 (d, C, JC–P = 7.1 Hz, C─COOCH3),
150.1 (C, C═O), 152.5 (C, C═O), 164.1–166.3 (C,
COOCH3), 168.1 (C, C─COOCH3), 169.2 (C,
C─COOCH3), 174.3 (d, C, JC–P = 5.5 Hz, COOCH3),
175.6 (d, C, JC–P = 5.5 Hz, COOCH3), 189.4 (d, C,
JC–P = 16.0 Hz, carbene).
31P{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 26.2. IR (KBr): νC═O = 1699,
1674 cm−1, νC─O = 1205 cm
−1. Anal. Calcd for
C45H43N4O10PPd (%): C 57.67, H 4.62, N 5.98. Found
(%): C 57.78, H 4.85, N 6.02.4.7.4 | Complex 3a
Brown microcrystals; yield 91%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 3.28 (s, 3H, OCH3), 3.42 (s,
3H, NCH3), 3.61 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 3.80
(s, 3H, OCH3), 3.84 (s, 3H, NCH3), 4.00 (d, 6H,
J = 2.1 Hz, 3NCH2P), 4.04 (s, 3H, NCH3), 4.20 (s, 3H,
NCH3), 4.49 (s, 6H, 3NCH2N).
13C{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 28.7 (CH3, NCH3), 32.0 (CH3,
NCH3), 37.0 (CH3, NCH3), 38.9 (CH3, NCH3), 50.9 (CH3,
OCH3), 51.1 (d, CH2, JC–P = 10.2 Hz, NCH2P), 51.2
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(d, CH2, JC–P = 6.4 Hz, NCH2N), 110.1 (C, C
5), 140.6 (C,
C4), 164.3–165.0 (C, COOCH3), 165.4 (C, C─COOCH3),
168.7 (C, C─COOCH3), 175.1 (d, C, JC–P = 5.7 Hz,
COOCH3), 177.3 (d, C, JC–P = 5.8 Hz, COOCH3), 186.9
(d, C, JC–P = 18.4 Hz, carbene).
31P{1H} NMR (CDCl3,
T = 298 K, δ, ppm): −64.8. IR (KBr): νC═O = 1711,
1672 cm−1, νC─O = 1206 cm
−1. Anal. Calcd for
C27H36N7O10PPd (%): C 42.89, H 4.80, N 12.97. Found
(%): C 42.72, H 4.93, N 12.82.4.7.5 | Complex 3b
Brown microcrystals; yield 90%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 3.23 (s, 3H, OCH3), 3.40 (s,
9H, 3NCH2P + NCH3), 3.53 (s, 3H, OCH3), 3.61 (s, 3H,
OCH3), 3.71 (s, 3H, OCH3), 3.78 (s, 3H, NCH3), 4.14 (s,
3H, NCH3), 4.06 and 4.20 (AB system, 6H, J = 14.8 Hz,
3NCH2N), 5.19 and 6.02 (AB system, 2H, J = 13.4 Hz,
NCH2), 7.34–7.44 (m, 5H, Ph).
13C{1H} NMR (CDCl3,
T = 298 K, δ, ppm): 28.8 (CH3, NCH3), 32.2 (CH3,
NCH3), 39.3 (CH3, NCH3), 50.1 (d, CH2, JC–P = 10.0 Hz,
NCH2P), 51.0 (CH3, OCH3), 51.3 (CH3, OCH3), 51.4
(CH3, OCH3), 51.6 (CH3, OCH3), 52.8 (CH2, NCH2), 72.7
(d, CH2, JC–P = 6.5 Hz, NCH2N), 110.1 (C, C
5),
128.6–136.5 (Ph), 140.6 (C, C4), 164.7–165.2 (C,
COOCH3), 166.6 (C, C─COOCH3), 167.7 (C,
C─COOCH3), 175.1 (d, C, JC–P = 5.5 Hz, COOCH3),
177.3 (d, C, JC–P = 5.9 Hz, COOCH3), 188.0 (d, C,
JC–P = 17.5 Hz, carbene).
31P{1H} NMR (CDCl3,
T = 298 K, δ, ppm): −66.7. IR (KBr): νC═O = 1709,
1670 cm−1, νC─O = 1242 cm
−1, 1207 cm−1. Anal. Calcd
for C33H40N7O10PPd (%): C 47.63, H 4.85, N 11.78. Found
(%): C 47.75, H 4.82, N 11.82.4.7.6 | Complex 3c
Brown microcrystals; yield 92%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 3.24 (s, 3H, OCH3), 3.60 (s,
3H, OCH3), 3.68 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.82
(s, 3H, NCH3), 4.00 (d, 6H, J = 2.0 Hz, 3NCH2P), 4.04
(s, 3H, NCH3), 4.20 (s, 3H, NCH3), 4.48 (s, 6H, 3NCH2N),
5.18 (s, 2H, NCH2), 7.32–7.50 (m, 5H, Ph).
13C{1H} NMR
(CDCl3, T = 298 K, δ, ppm): 32.0 (CH3, NCH3), 37.0
(CH3, NCH3), 39.0 (CH3, NCH3), 45.3 (CH2, NCH2), 50.9
(CH3, OCH3), 51.1 (d, CH2, JC–P = 10.3 Hz, NCH2P),
51.3 (CH3, OCH3), 51.4 (CH3, OCH3), 51.6 (CH3, OCH3),
73.1 (d, CH2, JC–P = 6.4 Hz, NCH2N), 110.1 (C, C
5),
128.0–136.2 (Ph), 140.8 (C, C4), 163.6–164.3 (C,
COOCH3), 165.4 (C, C─COOCH3), 168.9 (C,
C─COOCH3), 175.1 (d, C, JC–P = 5.5 Hz, COOCH3),
177.3 (d, C, JC–P = 5.7 Hz, COOCH3), 186.0 (d, C, JC–P = 18.7 Hz, carbene).
31P{1H} NMR (CDCl3, T = 298 K,
δ, ppm): −64.8. IR (KBr): νC═O = 1710, 1672 cm
−1,
νC─O = 1243, 1207 cm
−1. Anal. Calcd for
C33H40N7O10PPd (%): C 47.63, H 4.85, N 11.78. Found
(%): C 47.78, H 4.92, N 11.86.4.8 | Synthesis of mixed NHC–DIC
palladacyclopentadienyl complexes (4)
4.8.1 | Complex 4a
In a 50 ml two‐necked flask, 43.8 mg (0.112 mmol) of
[PdC4(COOCH3)4]n was dissolved in 5 ml of anhydrous
CH2Cl2 under inert atmosphere (argon). Amounts of
39.4 mg (0.0560 mmol) of complex Aga and 14.7 mg
(0.112 mmol) of DIC, suspended in 25 ml of anhydrous
CH2Cl2, were added to the solution of [PdC4
(COOCH3)4]n and precipitation of AgCl was immediately
observed. The mixture was reacted for 48 h at room tem-
perature and then filtered using a Millipore apparatus.
The clear brownish solution was concentrated under vac-
uum and the title complex precipitated by addition of
diethyl ether. The brownish microcrystalline precipitate
was filtered off using a Gooch filter, washed with diethyl
ether and dried under vacuum. An amount of 73.1 mg
(89% yield) of complex 4a was obtained.
1H NMR (400 MHz, CDCl3, T = 298 K, δ, ppm): 2.35 (s,
6H, 2CH3
DIC), 3.34 (s, 3H, OCH3), 3.41 (s, 3H, NCH3),
3.58 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.69 (s, 3H,
OCH3), 3.83 (s, 3H, NCH3), 4.14 (s, 3H, NCH3), 4.30 (s,
3H, NCH3), 7.12 (d, 2H, J = 8.1 Hz, 2H
meta), 7.23 (t, 1H,
J = 8.1 Hz, Hpara). 13C{1H} NMR (CDCl3, T = 298 K, δ,
ppm): 18.5 (CH3, CH3
DIC), 28.6 (CH3, NCH3), 32.0 (CH3,
NCH3), 37.1 (CH3, NCH3), 39.0 (CH3, NCH3), 51.0 (CH3,
OCH3), 51.3 (CH3, OCH3), 110.1 (C, C
5), 128.2–135.1
(PhDIC), 140.6 (C, C4), 145.9 (C, C─COOCH3), 147.7 (C,
C─COOCH3), 149.0 (C, CN), 150.5 (C, C═O), 153.1 (C,
C═O), 164.3 (C, COOCH3), 164.5 (C, COOCH3), 164.8
(C, C─COOCH3), 166.5 (C, C─COOCH3), 174.9 (C,
COOCH3), 175.6 (C, COOCH3), 185.8 (C, carbene). IR
(KBr): νC═N = 2176 cm
−1, νC═O = 1710, 1670 cm
−1,
νC─O = 1207 cm
−1. Anal. Calcd for C30H33N5O10Pd (%):
C 49.36, H 4.56, N 9.59. Found (%): C 49.52, H 4.68, N 9.47.
Derivatives 4b and 4c were prepared in a similar way
from the appropriate reactants.4.8.2 | Complex 4b
Yiellow microcrystals; yield 84%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 2.11 (s, 6H, 2CH3
DIC), 3.29
(s, 3H, OCH3), 3.35 (s, 3H, NCH3), 3.56 (s, 3H, OCH3),
3.66 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.84 (s, 3H,
14 of 16 SCATTOLIN ET AL.NCH3), 4.33 (s, 3H, NCH3), 5.60 and 5.94 (AB system, 2H,
J = 14.7 Hz, NCH2), 7.04–7.44 (m, 8H, Ph
DIC, PhBn).
13C{1H} NMR (CDCl3, T = 298 K, δ, ppm): 18.4 (CH3,
CH3
DIC), 28.7 (CH3, NCH3), 32.0 (CH3, NCH3), 39.3
(CH3, NCH3), 51.0 (CH3, OCH3), 51.1 (CH3, OCH3), 51.3
(CH3, OCH3), 51.4 (CH3, OCH3), 53.1 (CH2, NCH2),
109.7 (C, C5), 128.0–135.9 (Ph), 140.7 (C, C4), 145.7 (C,
C─COOCH3), 148.2 (C, C─COOCH3), 149.1 (C, CN),
150.5 (C, C═O), 152.8 (C, C═O), 163.7 (C, COOCH3),
164.6 (C, COOCH3), 164.8 (C, C─COOCH3), 166.9 (C,
C─COOCH3), 174.9 (C, COOCH3), 175.5 (C, COOCH3),
187.4 (C, carbene). IR (KBr): νC═N = 2177 cm
−1,
νC═O = 1710, 1670 cm
−1, νC─O = 1208 cm
−1. Anal. Calcd
for C36H37N5O10Pd (%): C 53.64, H 4.63, N 8.69. Found
(%): C 53.73, H 4.78, N 8.61.4.8.3 | Complex 4c
Yiellow microcrystals; yield 87%. 1H NMR (400 MHz,
CDCl3, T = 298 K, δ, ppm): 2.35 (s, 6H, 2CH3
DIC), 3.32
(s, 3H, OCH3), 3.57 (s, 3H, NCH3), 3.65 (s, 3H, OCH3),
3.69 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.15 (s, 3H,
NCH3), 4.28 (s, 3H, NCH3), 5.14 and 5.20 (AB system,
2H, J = 13.8 Hz, NCH2), 7.10–7.48 (m, 8H, Ph
DIC, PhBn).
13C{1H} NMR (CDCl3, T = 298 K, δ, ppm): 18.6 (CH3,
CH3
DIC), 32.0 (CH3, NCH3), 37.1 (CH3, NCH3), 39.0
(CH3, NCH3), 45.2 (CH2, NCH2), 51.0 (CH3, OCH3), 51.3
(CH3, OCH3), 51.4 (CH3, OCH3), 110.2 (C, C
5),
128.0–136.3 (Ph), 140.7 (C, C4), 145.8 (C, C─COOCH3),
147.7 (C, C─COOCH3), 149.0 (C, CN), 150.4 (C, C═O),
153.0 (C, C═O), 164.2 (C, COOCH3), 164.5 (C, COOCH3),
164.8 (C, C─COOCH3), 166.4 (C, C─COOCH3), 174.9 (C,
COOCH3), 175.6 (C, COOCH3), 186.0 (C, carbene). IR
(KBr): νC═N = 2178 cm
−1, νC═O = 1710, 1675 cm
−1,
νC─O = 1205 cm
−1. Anal. Calcd for C36H37N5O10Pd (%):
C 53.64, H 4.63, N 8.69. Found (%): C 53.51, H 4.69, N 8.72.4.9 | Cell growth evaluation
Cell viability inhibition assays were carried out using
human ovarian A2780 (cisplatin‐sensitive) and A2780cis
(cisplatin‐resistant) cancer cells and human lung fibroblast
MRC‐5 normal cells. The cells were obtained from ATCC
(Manassas, VA). The A2780 cell lines were maintained in
RPMI 1640, supplemented with 10% foetal bovine serum,
penicillin/streptomycin (100 U ml−1) and glutamine
(2 mM) (complete medium); to maintain the resistance,
1 μM cisplatin was routinely added to the A2780cis cells.
The pH of themediumwas 7.2 and the incubation was per-
formed at 37°C in a 5% CO2 atmosphere. Adherent cells
were routinely used at 70% of confluence and passagedevery 3 days by treatment with 0.25% trypsin–EDTA
(Sigma‐Aldrich, St Louis, MO, USA).
The MRC‐5 cells were maintained in Eagle's minimum
essential medium, non‐essential amino acids, 2 mM
L‐glutamine, 1 mM sodium pyruvate and 1500 mg l−1
sodium bicarbonate. To make the complete growth
medium, the following components were added to the
base medium: foetal bovine serum to a final concentra-
tion of 10% and penicillin/streptomycin (100 U ml−1).
All the derivatives were added at serial dilutions and
incubated in cell cultures: 50 mM stock solutions of each
complex were prepared using pure DMSO, and the work-
ing solutions (5 mM, 500 μM and 50 μM) were obtained
by successive dilution in EtOH. The water‐soluble deriva-
tives 3a–c were assayed also using aqueous solutions,
showing IC50 values comparable to those obtained with
DMSO–EtOH solutions. After 72 h of treatment, cells
were washed with PBS 1× and detached with trypsin.
Cells were then suspended in physiological solution and
counted with a Z2 Coulter Counter (Coulter Electronics,
Hialeah, FL, USA). The cell number per millilitre was
determined as IC50 after 3 days of culture, when
untreated cells were in log phase of cell growth.[11,25]
Cisplatin, solubilized in sterile water, was employed as
positive control and untreated cells were placed in every
plate as negative control. The cells were exposed to the
compounds in 1000 μl total volume.4.10 | Apoptosis assays
Annexin V and dead cell assays on A2780 and A2780cis
cells, untreated and treated for 72 h with increasing doses
of analysed derivatives, were performed with a Muse cell
analyser (Millipore, Billerica, MA, USA), according to
the instructions supplied by the manufacturer. This proce-
dure utilizes Annexin V to detect phosphatidylserine on
the external membrane of apoptotic cells. Moreover, a
dead cell marker is also utilized in the same kit as indicator
of cell membrane structural integrity. Cells were washed
with sterile PBS 1×, tripsinized, resuspended in the
original medium and diluted (1:1) with one‐step addition
of Muse Annexin V and Dead Cell reagent. After 20 min
of incubation at room temperature in the dark, samples
were analysed.[11] Data from prepared samples were
acquired and recorded utilizing the Annexin V and Dead
Cell Software Module (Millipore, Billerica, MA, USA).ACKNOWLEDGEMENTS
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